GLP-1 receptor agonists (GLP-1 RAs) have become a cornerstone of type 2 diabetes (T2D) treatment, with strong endorsements from the American Diabetes Association and the American Association of Clinical Endocrinology. Despite these clear guidelines, GLP-1 RAs remain significantly underutilized, as …
Lung cancer disproportionately affects many groups across the United States, including ethnic minorities and poor, rural, and military service individuals, with higher incidence and mortality rates. While there are many factors contributing to this observation, clinicians can address lung cancer …
Although bariatric surgery is an intervention proven to offer well-established benefits for obesity, notable disparities remain in referral rates, access to care, and postoperative outcomes, particularly among racial, ethnic, and low-income populations. Moreover, implicit biases in the health care setting …
GLP-1 receptor agonists (GLP-1 RAs) are revolutionizing glycemic control for patients with type 2 diabetes (T2D), but with rising clinical complexity and diverse patient needs, a one-size-fits-all approach is insufficient. While every currently available GLP-1 RA is indicated for blood …
A major hurdle in managing type 2 diabetes (T2D) is a widespread gap in clinician awareness around the powerful, far-reaching benefits of GLP-1 receptor agonists (GLP-1 RAs). These innovative therapies help reduce the burden of cardiovascular, kidney, and metabolic (CKM) …
Chronic, subacute, and acute pain remain among the most common and complex challenges encountered in clinical practice. Inadequate pain management contributes to diminished quality of life, impaired function, and increased healthcare utilization. At the same time, the ongoing opioid crisis …
Unlike many other cancers, rates of anal cancer and death due to anal cancer are rising in the United States. The increasing incidence is primarily seen in high-risk populations including men who have sex with men (MSM) and people living …
New diagnoses of HIV continue at a rapid pace despite the availability of preventative options. This is particularly true among underserved populations, including racial and ethnic minorities, who often go undiagnosed or underdiagnosed due to disparities in access to care. …
Individuals from underserved communities often face roadblocks to clinical trial participation, including geographic limitations, socioeconomic barriers, restrictive eligibility criteria, and systemic inequities. These challenges are compounded by unconscious bias among health care professionals (HCPs), which can shut down vital conversations …